These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 5023740)

  • 21. Dopamine agonist withdrawal syndrome: the apomorphine solution.
    Schlesinger I; Erikh I; Zaaroor M
    Arch Neurol; 2010 Sep; 67(9):1155; author reply 1156. PubMed ID: 20837868
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age-dependent.
    Zhu H; Barr GA
    Synapse; 2001 Jun; 40(4):282-93. PubMed ID: 11309844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pregabalin can cause addiction and withdrawal symptoms].
    Nordgaard J; Jürgens G
    Ugeskr Laeger; 2015 Jan; 177(2A):38-9. PubMed ID: 25612958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart.
    González-Cuello A; Sánchez L; Hernández J; Teresa Castells M; Victoria Milanés M; Laorden ML
    Eur J Pharmacol; 2007 Sep; 570(1-3):1-9. PubMed ID: 17601555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The substance P amino-terminal metabolite substance P(1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice.
    Kreeger JS; Larson AA
    J Pharmacol Exp Ther; 1996 Nov; 279(2):662-7. PubMed ID: 8930169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of agmatine on brain L-citrulline production during morphine withdrawal in rats: a microdialysis study in nucleus accumbens.
    Yananli H; Gören MZ; Berkman K; Aricioğlu F
    Brain Res; 2007 Feb; 1132(1):51-8. PubMed ID: 17182008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute psychiatric complications due to drug abuse and their therapy].
    Leuner H
    Nervenarzt; 1972 Mar; 43(3):142-5. PubMed ID: 5023736
    [No Abstract]   [Full Text] [Related]  

  • 29. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
    Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
    Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the treatment of stimulant abuse.
    Renault PF; Schuster CR
    Perspect Biol Med; 1972; 15(4):561-5. PubMed ID: 5040076
    [No Abstract]   [Full Text] [Related]  

  • 31. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine.
    Panchal V; Taraschenko OD; Maisonneuve IM; Glick SD
    Eur J Pharmacol; 2005 Nov; 525(1-3):98-104. PubMed ID: 16289028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acute alcoholic debauch. (Rehabilitation-oriented management of the withdrawal phenomena).
    Salzberger GJ
    Dis Nerv Syst; 1967 Jun; 28(6):387-9. PubMed ID: 6033178
    [No Abstract]   [Full Text] [Related]  

  • 33. A 24-h access I.V. self-administration schedule of morphine reinforcement and the estimation of recidivism: Pharmacological modification by arecoline.
    Buccafusco JJ; Bain JN
    Neuroscience; 2007 Nov; 149(3):487-98. PubMed ID: 17916413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbamazepine for withdrawal pseudohallucinations.
    Neppe VM
    Am J Psychiatry; 1988 Dec; 145(12):1605-6. PubMed ID: 3195683
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of agmatine on tolerance to and substance dependence on morphine in mice.
    Li J; Li X; Pei G; Qin BY
    Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):232-8. PubMed ID: 10452098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome.
    London ED; Kimes AS; Vaupel DB
    NIDA Res Monogr; 1995; 147():170-81. PubMed ID: 8742786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Metabolic correction of neurochemical disturbances in the striatum by the amino-acid-based drug tavamin on the experimental model of morphine abstinence syndrome].
    Kurbat MN; Lelevich VV; Kurbat NM
    Eksp Klin Farmakol; 2009; 72(5):15-7. PubMed ID: 19928569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca2+/calmodulin-dependent signal cascade.
    Hamdy MM; Noda Y; Miyazaki M; Mamiya T; Nozaki A; Nitta A; Sayed M; Assi AA; Gomaa A; Nabeshima T
    Behav Brain Res; 2004 Jul; 152(2):263-70. PubMed ID: 15196794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor.
    Valdez GR; Roberts AJ; Chan K; Davis H; Brennan M; Zorrilla EP; Koob GF
    Alcohol Clin Exp Res; 2002 Oct; 26(10):1494-501. PubMed ID: 12394282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of L-745,870, a dopamine D4 receptor antagonist, on naloxone-induced morphine dependence in mice.
    Mamiya T; Matsumura T; Ukai M
    Ann N Y Acad Sci; 2004 Oct; 1025():424-9. PubMed ID: 15542745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.